- Home
- IBRX vs AIN Comparison
IBRX vs AIN Comparison
Compare IBRX & AIN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IBRX
- AIN
- Stock Information
- Founded
- IBRX 2014
- AIN 1895
- Country
- IBRX United States
- AIN United States
- Employees
- IBRX N/A
- AIN N/A
- Industry
- IBRX Biotechnology: Biological Products (No Diagnostic Substances)
- AIN Textiles
- Sector
- IBRX Health Care
- AIN Consumer Discretionary
- Exchange
- IBRX Nasdaq
- AIN Nasdaq
- Market Cap
- IBRX 2.3B
- AIN 1.9B
- IPO Year
- IBRX N/A
- AIN 1987
- Fundamental
- Price
- IBRX $2.81
- AIN $70.07
- Analyst Decision
- IBRX Strong Buy
- AIN Buy
- Analyst Count
- IBRX 5
- AIN 5
- Target Price
- IBRX $11.40
- AIN $79.00
- AVG Volume (30 Days)
- IBRX 7.3M
- AIN 343.9K
- Earning Date
- IBRX 08-11-2025
- AIN 08-05-2025
- Dividend Yield
- IBRX N/A
- AIN 1.52%
- EPS Growth
- IBRX N/A
- AIN N/A
- EPS
- IBRX N/A
- AIN 2.49
- Revenue
- IBRX $31,222,000.00
- AIN $1,206,059,000.00
- Revenue This Year
- IBRX $567.98
- AIN $0.19
- Revenue Next Year
- IBRX $160.56
- AIN $4.14
- P/E Ratio
- IBRX N/A
- AIN $27.98
- Revenue Growth
- IBRX 10238.41
- AIN 1.17
- 52 Week Low
- IBRX $1.83
- AIN $57.71
- 52 Week High
- IBRX $7.48
- AIN $95.47
- Technical
- Relative Strength Index (RSI)
- IBRX 51.33
- AIN 52.16
- Support Level
- IBRX $2.68
- AIN $68.83
- Resistance Level
- IBRX $3.00
- AIN $71.79
- Average True Range (ATR)
- IBRX 0.16
- AIN 1.57
- MACD
- IBRX -0.00
- AIN -0.04
- Stochastic Oscillator
- IBRX 62.00
- AIN 36.02
About IBRX ImmunityBio Inc.
ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: the United States and Europe. Key revenue is generated from the United States.
About AIN Albany International Corporation
Albany International Corp is principally engaged in processing textiles and materials. The company consists of two business segments, the machine clothing segment, which produces and provides custom-designed fabrics and belts for the production in the paper, nonwovens, and other process industries; and the Albany engineered composites segment, which offers engineered composite parts for the aerospace and defensive industries. The machine clothing segment contributes to the majority of the company's total revenue. The company has an operation and generates revenue from the United States, Switzerland, Brazil, China, Mexico, France, and other areas.